Oral Abstract Session - Pediatric Oncology I
Oral Abstract Session - Pediatric Oncology II
Poster Discussion Session - Pediatric Oncology

Oral Abstract Session - Pediatric Oncology I

High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.

Abstract: 10000: Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau Couanet, et al.

Presenter: Ruth Lydia Ladenstein MD, MBA

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.

Abstract: 10001: Selim Corbacioglu, Holger Lode, Marcus Jakob, et al.

Presenter: Selim Corbacioglu

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.

Abstract: 10002: Tara Henderson, Jenna Bardwell, Pei-Chi Kao, et al.

Presenter: Tara O. Henderson, MD, FASCO, MPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.

Abstract: 10003: Jacques Grill, Gwenael Le Teuff, Pascale Varlet, et al.

Presenter: Jacques /. Grill

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.

Abstract: 10004: Lindsay Kilburn, Dong-Anh Khuong-Quang, Karsten Nysom, et al.

Presenter: Lindsay Baker Kilburn

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Treatment of focal anaplastic Wilms tumor (FAWT): A Children’s Oncology Group (COG) report from AREN0321 and AREN03B2 studies.

Abstract: 10005: Amy Armstrong, Najat Daw, Lindsay Renfro, et al.

Presenter: Amy E. Armstrong, MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).

Abstract: 10006: Margaret Macy, Rajen Mody, Joel Reid, et al.

Presenter: Margaret E Macy MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Abstract: 10007: Alice Lee, Alexander Chou, P. Williams, et al.

Presenter: Alice Lee MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Abstract: 10008: Theodore Laetsch, Kathleen Ludwig, David Hall, et al.

Presenter: Theodore Willis Laetsch, MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session, you need an ASCO Annual Meeting registration.

-------------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Pediatric Oncology

Oral Abstract Session - Pediatric Oncology II

Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.

Abstract: 10009: Haley Newman, Emily Jones, Puja Umaretiya, et al.

Presenter: Haley Newman MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

Abstract: 10010: Emily Jones, Arlene Naranjo, Lena Winestone, et al.

Presenter: Emily Jones, BS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).

Abstract: 10011: Xu Ji, Xin Hu, Ann Mertens, et al.

Presenter: Xu Ji

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.

Abstract: 10012: Eric Chow, Kayla Stratton, Saro Armenian, et al.

Presenter: Eric Jessen Chow MD, MPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.

Abstract: 10013: Saro Armenian, Melissa Hudson, Lanie Lindenfeld, et al.

Presenter: Saro Armenian

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Clonal hematopoiesis in survivors of childhood cancer.

Abstract: 10014: Danielle Friedman, Irenaeus Chan, Chaya Moskowitz, et al.

Presenter: Danielle Novetsky Friedman MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.

Abstract: 10015: Ti-Cheng Chang, Wenan Chen, Abdelrahman Elsayed, et al.

Presenter: Ti-Cheng Chang

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.

Abstract: 10016: Maureen O'Brien, Jennifer McNeer, Susan Rheingold, et al.

Presenter: Maureen Megan O'Brien, MD, MS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).

Abstract: 10017: Edoardo Pennesi, Erica Brivio, Marieke Willemse, et al.

Presenter: Edoardo Pennesi

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session, you need an ASCO Annual Meeting registration.

--------------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Pediatric Oncology

Poster Discussion Session - Pediatric Oncology

Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.

Abstract: 10018 | Poster Bd #: 324: Qing Zhou, Yi-Long Wu, Xiangqian Zheng, et al.

Presenter: Frank Y. Lin MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.

Abstract: 10019 | Poster Bd #: 325: Pablo Berlanga, Liora Brunel, Isabelle Aerts, et al.

Presenter: Pablo Berlanga

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.

Abstract: 10020 | Poster Bd #: 326: Fernando Carceller, Harm van Tinteren, Alicia Castañeda, et al.

Presenter: Fernando Carceller

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.

Abstract: 10021 | Poster Bd #: 327: Chinwe Udemgba, Karen Hoehn, Wendy Darlington, Brett Palama

Presenter: Chinwe Udemgba

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Identifying osteosarcoma signatures in cell free DNA using 5-hydroxymethylcytosine profiling.

Abstract: 10022 | Poster Bd #: 328: Evan Neczypor, Kelly Moore, Elizabeth Zeldin, et al.

Presenter: Evan William Neczypor

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.

Abstract: 10023 | Poster Bd #: 329: Xiaojie Hu, JinHu Wang, Wenbin Li, et al.

Presenter: Xiaojie Hu

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.

Abstract: 10024 | Poster Bd #: 330: Thomas Cash, Dolly Aguilera, Kevin Ginn, et al.

Presenter: Thomas Cash, MD, MSc

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.

Abstract: 10025 | Poster Bd #: 331: Lyn Balsamo, John Kairalla, Emily Hibbitts, et al.

Presenter: Nina S. Kadan-Lottick, MD, MSPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.

Abstract: 10026 | Poster Bd #: 332: Anurekha Hall, Devan Duenas, Jenna Voutsinas, et al.

Presenter: Anurekha Gollapudi Hall, MD, MS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Abstract: 10027 | Poster Bd #: 333: Luciana Vinti, Stephen Daw, Constantino Sabado Alvarez, et al.

Presenter: Luciana Vinti

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Accelerated brain age and associated neurocognitive impairments in adult survivors of childhood cancer.

Abstract: 10028 | Poster Bd #: 334: Nicholas Phillips, Jessica Baedke, AnnaLynn Williams, et al.

Presenter: Nicholas Steve Phillips MD, PhD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Genetic study of type 2 diabetes risk in diverse populations of survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).

Abstract: 10029 | Poster Bd #: 335: Cindy Im, Achal Neupane, Jessica Baedke, et al.

Presenter: Cindy Im, PhD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.